Surf Air Mobility

ARCELLX (NASDAQ: ACLX) STOCK QUOTE

Last Trade: US$55.79 0.73 1.33
Volume: 558,723
5-Day Change: 5.70%
YTD Change: 0.52%
Market Cap: US$2.980B

LATEST NEWS FROM ARCELLX

The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as the successful technical transfer is complete Remain on track to present preliminary data from the iMMagine-1 trial by end of the year REDWOOD CITY,... Read More
The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as the successful technical transfer is complete Remain on track to present preliminary data from the iMMagine-1 trial by end of the year REDWOOD CITY,... Read More
REDWOOD CITY, Calif. / May 09, 2024 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Cash, cash equivalents, and marketable... Read More
REDWOOD CITY, Calif. / May 07, 2024 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in two upcoming investor conferences: BofA Securities Health Care Conference 2024 (In Person) Presentation: Tuesday, May 14 at 3:40 p.m.... Read More
REDWOOD CITY, Calif. / Apr 04, 2024 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET. A live webcast of... Read More
REDWOOD CITY, Calif. / Mar 20, 2024 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET. A live... Read More
REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6 , at 2:50 p.m. ET . A live webcast of this... Read More
Expanded strategic partnership with Kite Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory multiple myeloma Ended the quarter with $729.2M , extending cash runway into 2027 REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the... Read More
Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months The estimated median progression free survival by Kaplan-Meier is 28 months Oral presentation at ASH will be on Monday, December 11, 2023 at 5 p.m. PT Company to host a live webcast event with an expert panel of clinicians on Monday, December 11 at 8 p.m.... Read More
Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas REDWOOD CITY, Calif. and SANTA MONICA, Calif. , Nov. 15, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ:... Read More
Recently released ASH abstract for the company's Phase 1 CART-ddBCMA trial demonstrated that median duration of response, progression free survival, and overall survival not reached with median follow-up of 22 months after CART-ddBCMA infusion Company to present new patient data from its Phase 1 CART-ddBCMA trial during an oral presentation with a median follow-up of 26.5 months at the 65th ASH Annual Meeting in December... Read More
Abstract released today is from a June 2, 2023 data cut Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA infusion of 22 months A more recent data cut will be shared during the oral presentation with a median follow-up of 26.5 months Company to host a live webcast event with an expert panel of clinicians REDWOOD CITY, Calif. , Nov. 2, 2023... Read More
REDWOOD CITY, Calif. , Oct. 26, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that the management team will participate in two upcoming investor conferences: TD Cowen 7th Annual Fall Oncology Innovation Summit (Virtual) Fireside Chat: Friday,... Read More
Company expects to present preliminary data from iMMagine-1 study in 2H'24 REDWOOD CITY, Calif. , Aug. 14, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the... Read More
FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion REDWOOD CITY, Calif. , June 19, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that it has received notification from the U.S. Food and... Read More
REDWOOD CITY, Calif. , May 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the first quarter ended March 31, 2023 . "Delivering our novel CAR-T therapy to multiple myeloma patients is at the heart of our mission," said Rami... Read More
REDWOOD CITY, Calif. , April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023 , at 1:00 p.m. ET.... Read More
Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma Presented continued robust long-term responses from CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma Enrolled and dosed patients in pivotal iMMagine-1 clinical program for patients with rrMM Initiated ACLX-002 for patients with AML/MDS REDWOOD CITY, Calif.... Read More
REDWOOD CITY, Calif. , Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 , at 1:00 p.m. ET . A live webcast... Read More
REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the company's participation in the following investor conferences: Guggenheim Oncology Conference 2023 Fireside chat on Thursday, February 9, 2023 , at 11:20 a.m. ET SVB... Read More
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for... Read More
100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors 27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%) dosed > 12 months ago or had their 12-month follow-up visit by November 22, 2022 have reached CR/sCR No cases of Grade >3 CRS at RP2D and no delayed neurotoxicity or parkinsonian-like events First patients dosed in iMMagine-1 Phase 2... Read More
Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory... Read More
Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. Arcellx to continue independently... Read More
Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 64th ASH Annual Meeting in December Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, December 11, 2022 , at 11:00 AM CT REDWOOD CITY, Calif. , Nov. 14, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:... Read More
ASH abstract contains previously presented data from June 2022 New clinical data from a recent data cut will be presented at ASH Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, December 11, 2022 , at 11:00 a.m. CT Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients... Read More
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 , at 3:30 p.m. ET . A live webcast of the discussion will be accessible from... Read More
Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters' option to purchase additional shares Presented continued robust long-term responses from its CART-ddBCMA Phase 1 expansion trial being evaluated in patients with r/r MM at the 2022 ASCO Annual Meeting Preclinical results from CART-ddBCMA published in Molecular Cancer Therapeutics Arcellx,... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS